Mortality due to tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Time taken from start of treatment until the resolution of DIOS · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure rate · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Episodes of acute DIOS · adults and children with cystic fibrosis
1 finding from 1 review
Adverse effects: abdominal mass · adults and children with cystic fibrosis
1 finding from 1 review
Abdominal pain · adults and children with cystic fibrosis
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in clinical improvement: discharged alive ( compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review